Fibroblast Growth Factor 19 Improves LPS-Induced Lipid Disorder and Organ Injury by Regulating Metabolomic Characteristics in Mice

Figure 5

Pathway enrichment analysis using pathway-associated metabolite sets (SMPDB) and pathway analysis bubble plot by mmu set. Mice were divided into four groups including control, LPS, only FGF19 treatment (FGF19), and pretreatment with FGF19 followed by LPS administration (FGF19 + LPS) (). (a, b) Pathway enrichment analysis. Different colors represent different values. The smaller value, the redder the color is. The length of line segment in SMPDB represents fold enrichment. (c, d) Pathway analysis bubble plot by mmu set. The abscissa of pathway analysis bubble plot represents pathway impact, and the ordinate indicates -ln(p). (a, c) LPS vs. control, (b, d) FGF19 + LPS vs. LPS. The concentration of differentially significant metabolites in common pathway between LPS vs. control and FGF19 + LPS vs. LPS. (e) Linoleic acid, (f) gamma-linolenic acid, (g) dihomo-gamma-linolenic acid, and (h) (DHA). indicates for LPS vs. control, and ^# indicates for FGF19+LPS vs. LPS, using Student’s t-test. Each black point represents a sample.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)